Braintree Laboratories, Inc.
$33.9M 5,369 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. reported $33,688,659.48 across General Payments, Research, and Ownership to 4,888 physicians and teaching hospitals across 5,618 transactions.
- $33.7M Top 10% payer
- All-tracks total
- 5,618 Top quartile volume
- Transactions
- 4,888 Top quartile reach
- Recipients
- −$1.4M
- General Payments vs PY2023
Mirati Therapeutics, Inc. reported $33,688,659.48 across all CMS Open Payments tracks (General + Research + Ownership) to 4,888 physicians and teaching hospitals in Program Year 2024 - ranking #64 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $321,960.65, averaging $6.9K per recipient.
How Mirati Therapeutics, Inc.'s $33.7M all-tracks total breaks down
Mirati Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
72/100
Total payments
A
100/100
Transaction volume
D
51/100
Physician reach
F
47/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mirati-therapeutics-inc Mirati Therapeutics, Inc.
$33.7M · #64/1,925 · 0.2% industry · PY2024
- TOT $33.7M
- RANK #64
- SHARE 0.2%
- TXN 5,618
- RCP 4,888
- CAT 7
- GEN $322.0K
- ΔGEN −$1.4M
- TOP1 7.1%
- PY 2024
Volume peers
Nearest volume peer: Braintree Laboratories, Inc. ($33.9M)
Mirati Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Mirati Therapeutics, Inc.'s CMS-reported General Payments decreased by $1.4M (−81.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: MIRATI THERAPEUTICS, INC.PY2024: Mirati Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,694,775.15
- PY2024
- $321,960.65
What the Data Shows for Mirati Therapeutics, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Mirati Therapeutics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 7-category general-payment breakdown below at $110.0K (34.2% of General Payments, 4,729 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 7 types of general payments, Mirati Therapeutics, Inc.'s largest category was "Food and Beverage" at $110.0K - 34.2% of General Payments.
Mirati Therapeutics, Inc. reports 7 general-payment categories - the top three are Food and Beverage (34.2%), Honoraria (26.4%), and Space Rental or Facility Fees (15.1%). The remaining 4 categories make up 24.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Mirati Therapeutics, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $110.0K | 4,729 | 34.2% |
| Honoraria | $84.9K | 34 | 26.4% |
| Space Rental or Facility Fees | $48.7K | 19 | 15.1% |
| Consulting Fee | $42.6K | 24 | 13.2% |
| Travel and Lodging | $30.5K | 65 | 9.5% |
| Grant | $5.0K | 1 | 1.6% |
| Education | $244.71 | 16 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $72,076.58 (22.4%) of $321,960.65 in this company's General Payments records across 3,129 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Mirati Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Hatim Husain
$23,014.63 across 13 reported transactions
- 2
Kathryn C. Arbour
$15,668.80 across 5 reported transactions
- 3
Mohamed Mohamed
$12,474.52 across 11 reported transactions
- 4
Martin Dietrich
$11,195.63 across 13 reported transactions
- 5
Eugene Muchnik
$9,723.00 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Mirati Therapeutics, Inc. ranks #64 of 1,925 by total payments (top 3% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,588 of 1,838 by HHI (bottom 14% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Omeza LLC : $1.5K total payments, HHI 178
- Caldera Medical, Inc : $117.1K total payments, HHI 177
- Karyopharm Therapeutics Inc. : $1.0M total payments, HHI 177
- Sagent Pharmaceuticals : $1.0K total payments, HHI 177
- Rigel Pharmaceuticals, Inc. : $1.0M total payments, HHI 175
- Servier Pharmaceuticals LLC : $1.5M total payments, HHI 174
- Mirati Therapeutics, Inc. (this company) : $322.0K total payments, HHI 171
- Sekisui Diagnostics, LLC : $21.5K total payments, HHI 171
- Baxter Healthcare : $4.8M total payments, HHI 171
- Fresenius USA Marketing, Inc. : $709.1K total payments, HHI 171
- Alpha Orthopedic Systems : $28.4K total payments, HHI 169
- Calliditas Therapeutics US Inc. : $2.0M total payments, HHI 169
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Mirati Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Mirati Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Mirati Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Kite Pharma, Inc.
$34.1M 2,852 recipients
Compare payment profiles
SN Holdings, LLC
$32.8M 35 recipients
Compare payment profiles
Alexion Pharmaceuticals, Inc.
$34.7M 48,499 recipients
Compare payment profiles
Allerderm Laboratories
$32.7M 5 recipients
Compare payment profiles
Janssen Biotech, Inc.
$31.5M 298,174 recipients
Compare payment profiles
Put this to use
Mirati Therapeutics, Inc. ranks #64 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Mirati Therapeutics, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Mirati Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.